[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
BT Li, EF Smit, Y Goto, K Nakagawa… - … England Journal of …, 2022 - Mass Medical Soc
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
[HTML][HTML] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J Naidoo, DB Page, BT Li, LC Connell, K Schindler… - Annals of …, 2015 - Elsevier
Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1
pathway have demonstrated antitumor activity across multiple malignancies, and gained …
pathway have demonstrated antitumor activity across multiple malignancies, and gained …
[HTML][HTML] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
…, G Friberg, P Lito, R Govindan, BT Li - … England Journal of …, 2020 - Mass Medical Soc
Background No therapies for targeting KRAS mutations in cancer have been approved. The
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to …
KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to …
[HTML][HTML] Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Background Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
[PDF][PDF] The genomic landscape of endocrine-resistant advanced breast cancers
…, S Modi, TA Traina, C Dang, W Zhang, B Weigelt, BT Li… - Cancer cell, 2018 - cell.com
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
Diverse alterations associated with resistance to KRAS (G12C) inhibition
Inactive state-selective KRAS(G12C) inhibitors 1 , 2 , 3 , 4 , 5 , 6 , 7 – 8 demonstrate a 30–40%
response rate and result in approximately 6-month median progression-free survival in …
response rate and result in approximately 6-month median progression-free survival in …
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively)
are found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
are found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
…, A Zehir, N Rekhtman, MS Ginsberg, BT Li… - Cancer discovery, 2017 - AACR
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA
(cfDNA) requires understanding of the various biological compartments contributing to the …
(cfDNA) requires understanding of the various biological compartments contributing to the …
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
The efficacy of KRAS G12C inhibitors in NSCLC and colorectal cancer is lineage-specific.
RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance …
RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance …